Hematopoiesis News Volume 14.33 | Aug 22 2023

    By
    Jamie Kang
    -
    0
    16







    2023-08-22 | HN 14.33


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.33 – 22 August, 2023
    TOP STORY

    PPM1D Modulates Hematopoietic Cell Fitness and Response to DNA Damage and Is a Therapeutic Target in Myeloid Malignancy

    Scientists showed that while Ppm1d activation conferred cellular resistance to cytotoxic therapy, it did so to a lesser degree than p53 loss. Notably, loss of Ppm1d sensitized leukemias to cytotoxic therapies in vitro and in vivo, even in the absence of a Ppm1d mutation.
    [Blood]

    Abstract
    As a scientist, how you separate the facts from the claims is just as important as how you separate your cells. See for yourself.
    PUBLICATIONSRanked by the impact factor of the journal

    GATA2 Mitotic Bookmarking Is Required for Definitive Hematopoiesis

    Investigators addressed mitotic retention of the hemogenic factors GATA2, GFI1B, and FOS during hematopoietic specification. They showed that GATA2 remains bound to chromatin throughout mitosis, in contrast to GFI1B and FOS, via C-terminal zinc finger-mediated DNA binding.
    [Nature Communications]

    Full Article

    S1P-S1PR3-RAS Promotes the Progression of S1PR3hi TAL1+ T-Cell Acute Lymphoblastic Leukemia That Can Be Effectively Inhibited by an S1PR3 Antagonist

    By investigating the transcriptome and prognosis of T cell acute lymphoblastic leukemia (T-ALL) from multiple cohorts, researchers found that S1PR3 was highly expressed in a subset of TAL1+ T-ALL, which showed poor outcomes.
    [Leukemia]

    AbstractGraphical Abstract

    TAL1 Hijacks MYCN Enhancer That Induces MYCN Expression and Dependence on Mevalonate Pathway in T-Cell Acute Lymphoblastic Leukemia

    Investigators first identified an evolutionarily conserved enhancer element controlling the MYCN oncogene that was aberrantly activated by the TAL1 complex in T cell acute lymphoblastic leukemia cells.
    [Leukemia]

    Abstract

    LMO2 Promotes the Development of AML through Interaction with Transcription Co-Regulator LDB1

    The LIM-only protein 2 (LMO2) gene was knocked down to observe its effects on the proliferation, survival, and colony formation of NB4, Kasumi-1, and K562 cell lines. Furthermore, in vitro and in vivo experiments revealed that LDB1 was essential for the proliferation and survival of AML cell lines.
    [Cell Death & Disease]

    Full Article

    FANCA Deficiency Promotes Leukemic Progression by Allowing the Emergence of Cells Carrying Oncogenic Driver Mutations

    Investigators assessed the functional consequences of deleting the Fanconi anemia A (Fanca) gene, which encodes a DNA damage response protein, in Spi1 transgenic mice that develop the preleukemic syndrome.
    [Oncogene]

    Full Article

    Accessory-Cell-Free Differentiation of Hematopoietic Stem and Progenitor Cells into Mature Red Blood Cells

    Scientists described the near-complete erythroid differentiation of cultured red blood cells from adult hematopoietic stem and progenitor cells in accessory-cell-free and xeno-free conditions.
    [Cytotherapy]

    Abstract

    Treosulfan-Based Conditioning Regimen in Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)

    Investigators reported the results of a retrospective observational study aiming to describe the outcomes and safety of pediatric patients treated in Spain with treosulfan-based conditioning before hematopoietic stem cell transplantation after data collection from electronic clinical records.
    [Transplantation And Cellular Therapy]

    Abstract

    Reduced Post-transplant Cyclophosphamide Dose with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

    Scientists compared the outcomes with a reduced Post-transplant cyclophosphamide (PT-Cy) total dose to those with the standard PT-Cy dose in haploidentical hematopoietic cell transplantation patients aged ≥ 65 years and those with cardiac comorbidities.
    [Bone Marrow Transplantation]

    Abstract
    Getting enough cord blood HSCs for transplantation isn't easy. But she's paving the way. Watch Suzan Imren's webinar.
    REVIEWS

    Immunotherapy in Hematologic Malignancies: Achievements, Challenges, and Future Prospects

    The authors review historical perspectives on the applications and clinical considerations of immunotherapy. They first outline the recent advances that have been made in the understanding of the various categories of immunotherapies in the treatment of hematologic malignancies.
    [Signal Transduction And Targeted Therapy]

    Full Article
    INDUSTRY AND POLICY NEWS

    Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML

    Gilead Sciences, Inc. announced that the US FDA has placed a partial clinical hold on the initiation of new patients in US studies evaluating magrolimab to treat AML.
    [Gilead Sciences, Inc.]

    Press Release
    FEATURED EVENT

    Trafficking Pathways in Neurodegeneration

    September 6 – 8, 2023
    Hinxton, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Research Assistant – Leukemia

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Post Doctoral Fellow – Autoimmunity and Transplantation

    University of Missouri – Columbia, Missouri, United States

    Research Associate – Recombinant Protein

    Creative Biolabs – New York, New York, United States

    Postdoctoral Scientist – Cancer Research Cluster

    Cedars-Sinai – Los Angeles, California, United States

    Postdoctoral Project Research Scientist – Signaling and Structural Laboratory

    Francis Crick Institute – London, England, United Kingdom
    Brought to you by

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter